Meningococcal Vaccination in 25-Year-Old with Sickle Cell Disease and Autosplenectomy
Yes, meningococcal vaccine is absolutely indicated and should be administered as a 2-dose primary series of MenACWY given at least 8 weeks apart, plus a MenB vaccine series, with ongoing boosters every 5 years for MenACWY and every 2-3 years for MenB. 111
Primary Vaccination Schedule
MenACWY (Serogroups A, C, W, Y)
For patients ≥10 years with anatomic or functional asplenia (including sickle cell disease with autosplenectomy):
- Primary series: 2 doses given at least 8 weeks apart
- Choose any of: MenACWY-D (Menactra), MenACWY-CRM (Menveo), or MenACWY-TT (MenQuadfi)
- Important timing consideration: If using MenACWY-D, ensure it's given at least 4 weeks after completion of PCV13 series to avoid interference with pneumococcal vaccine response 11
MenB (Serogroup B)
For patients ≥10 years with asplenia:
- Option 1: MenB-FHbp (Trumenba) - 3 doses at 0,1-2, and 6 months
- Option 2: MenB-4C (Bexsero) - 2 doses at least 1 month apart
- Critical note: These two vaccines are NOT interchangeable - use the same product for all doses 11
Booster Schedule (Lifelong)
Since your patient remains at increased risk due to persistent asplenia:
- MenACWY booster: Single dose at 5 years after primary vaccination, then every 5 years thereafter 11
- MenB booster: Single dose at 1 year after completion of primary vaccination, then every 2-3 years thereafter 11
Key Clinical Considerations
Licensing caveat: MenB vaccines are only FDA-licensed for ages 10-25 years, so at age 25, your patient is technically at the upper age limit. However, vaccination at age 26+ is considered off-label but still recommended by ACIP for high-risk patients 12. Given the patient is currently 25, vaccinate now without delay.
Why this matters for mortality/morbidity: Patients with functional or anatomic asplenia face lifelong risk of overwhelming post-splenectomy infection (OPSI) from encapsulated organisms. While recent systematic review data 3 surprisingly found minimal IMD cases in SCD patients historically (only 5 cases across studies from 1965-1995), this likely reflects the success of vaccination programs rather than absence of risk. The biological rationale remains sound - asplenia creates vulnerability to encapsulated bacteria including Neisseria meningitidis 4.
Practical implementation: Coordinate with pneumococcal vaccination if not already completed. The patient should have received PCV13 followed by PPSV23, with MenACWY-D given at least 4 weeks after PCV completion 11.
Documentation and follow-up: Establish a tracking system for the 5-year MenACWY and 2-3 year MenB booster schedule, as adherence to ongoing boosters is often suboptimal despite clear recommendations 4.